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Progress towards realizing a vision of personalized medicine—drugs and drug doses that 
are safer and more effective because they are chosen based on an individual’s genetic makeup—
has been slower than once forecast.  The Food and Drug Administration has a key role to play in 
facilitating the use of genetic information in drug therapies because it approves labels, and labels 
influence how doctors use drugs. Here we evaluate one example of how using genetic 
information in drug therapy may improve public health and lower health care costs.   
 
  Warfarin, an anticoagulant commonly used to prevent and control blood clots, is 
complicated to use because the optimal dose varies greatly among patients. If the dose is too 
strong the risk of serious bleeding increases and if the dose is too weak, the risk of stroke 
increases. We estimate the health benefits and the resulting savings in health care costs by using 
personalized warfarin dosing decisions based on appropriate genetic testing. We estimate that 
formally integrating genetic testing into routine warfarin therapy could allow American warfarin 
users to avoid 85,000 serious bleeding events and 17,000 strokes annually. We estimate the 
reduced health care spending from integrating genetic testing into warfarin therapy to be $1.1 
billion annually, with a range of about $100 million to $2 billion. 
 1 
Health Care Savings from Personalizing Medicine Using Genetic Testing: 
The Case of Warfarin 
 




The vision of personalized medicine—drugs and drug doses that are safer and more 
effective because they are chosen according to an individual’s genetic makeup—has grown 
closer with the Administration’s request for six million dollars in funding for the Critical Path 
Initiative of the Food and Drug Administration (FDA).
1 This Initiative can protect and promote 
public health by generating information needed to identify patients likely to benefit from a 
treatment as well as patients more likely to respond adversely to a drug.
2  Through collaboration 
with the new Critical Path Institute (C-Path) and the University of Utah, the FDA is already 
working to establish an evidence-based framework for determining the clinical utility of 
cardiovascular biomarkers.   These include genetic variants that determine the response to 
warfarin —a commonly used anticoagulation drug whose wide range of efficacy in different 
individuals can expose many tens of thousands of patients to severe under- or over-dosing.
3 
Improving warfarin therapy by integrating genetic testing into dosing protocols will require not 
only the collection of additional data demonstrating the clinical value of such testing, but also 
changes to warfarin labeling. FDA thus plays a key role because it approves drug labels 
describing appropriate use and these, in turn, influence physician practice.
4 The case of warfarin 
dosing illustrates how FDA is uniquely positioned both to cooperate in clearing scientific hurdles 
that impair improvements in medicine and to facilitate adoption of these improvements by 
improving labeling.  As we demonstrate below, the case of warfarin also illustrates how FDA-
facilitated improvements in drug dosing based on newly available genetic tests can 
simultaneously improve public health and offer large savings to health care payers.   
                                            
1 Department of Health and Human Services News Release, HHS Proposes $689 Billion Budget for Fiscal Year 
2007, February 6
th 2006, http://www.hhs.gov/news/press/2006pres/20060206a.html.  
2 Food and Drug Administration, Budget Formulation and Presentation, The Critical Path to Personalized Medicine, 
February 2006, http://www.fda.gov/oc/oms/ofm/budget/2007/HTML/4CPPOM1.htm.  
3 Food and Drug Administration, FDA Drug Safety Initiative: Fact Sheet, 2006 
http://www.fda.gov/oc/factsheets/initiative.html.  
4 Warfarin is included in the FDA’s Critical Path Initiative. See Food and Drug Administration, “FDA Drug Safety 
Initiative: Fact Sheet,” 2006, http://www.fda.gov/oc/factsheets/initiative.html. 
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The anticoagulant medication warfarin is used to prevent and treat blood clots. 
Approximately 2 million persons start taking warfarin each year; physicians commonly prescribe 
it for patients with a history of atrial fibrillation, recurrent stroke, deep vein thrombosis, or 
pulmonary embolism, as well as for patients who have had heart valve replacements. A major 
challenge in treating patients with warfarin is that the optimal dose varies greatly from person to 
person. Further, if the dose taken is too high, users are subject to increased risk of serious 
bleeding.  Indeed, warfarin is the second most common drug—after insulin—among those 
implicated in emergency room visits for adverse drug events, causing an average of more than 
43,000 cases per year in 2004-2005.
5 Finally, if the dose is too low, users are subject to increased 
risk of stroke.  
Currently, the appropriate dose is determined by monitoring the level of anticoagulation 
through blood tests and altering the dose if it is too high or too low. Recent research shows 
genetic tests can, to some extent, identify which patients require higher and lower doses and may 
be a cost effective way to reduce bleeding events from warfarin.
6 We estimate that formally 
integrating genetic testing into routine warfarin therapy could allow American warfarin users to 
avoid 85,000 serious bleeding events and 17,000 strokes annually. 
Our model may underestimate the full benefits of integrating genetic information into 
warfarin dosing because it includes the effects of over-dosing warfarin in only some genetic 
variants-- the presence of one or more 2C9 variant alleles. Sconce et al.
7 show polymorphisms at 
a second genetic locus, VKORC, are independently strongly correlated with the warfarin 
maintenance dose. Variation in the VKORC enzyme is, therefore, another risk factor for 
bleeding. Genetic testing for both CYP2C9 and VKORC could reduce bleeding events and 
                                            
5 Daniel S. Budnitz et al., “National Surveillance of Emergency Department Visits for Outpatient Adverse Drug 
Events.” JAMA 2006; 296: 1858-1866.  The cases that are seen in emergency departments represent a subset of total 
adverse drug events but the precise fraction they represent is uncertain. An estimate of total adverse drug events 
would include those occurring among hospital and nursing home inpatients, those treated in clinics, offices, and 
homes, and those not treated – in addition to those treated in emergency departments.  
6 Tom Schalekamp et al., “CYP2C9 Genotyping in Acenocoumarol Treatment: Is It a Cost-Effective Addition to 
International Normalized Ratio Monitoring?” Clinical Pharmacology and Therapeutics 2006; 79: 511-520. 
7 Elizabeth A. Sconce et al., “The Impact of CYP2C9 and VKORC1 Genetic Polymorphism and Patient 
Characteristics upon Warfarin Dose Requirements: Proposal for a New Dosing Regimen.” Blood 2005; 106: 2329-
2333. 
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strokes that occur in warfarin therapy by more than the annual estimates of 85,000 and 17,000 
developed here.
8   
Excluding the potential benefits of testing for VKORC variation, we estimate the net 
monetary benefits of integrating genetic testing into warfarin therapy to include $1.1 billion 
annually in reduced health care spending, with a range from $100 million to $2 billion annually.  
These estimates of potential benefits illustrate the gains that might be achieved through 
successful implementation of one part of the FDA’s Critical Path Initiative. The Initiative seeks 
to identify  ways of predicting drug safety and efficacy, and to develop standards and other 
innovations that facilitate application of basic scientific advances to the improvement of patients’ 
health.  In many cases, the gap between science and improved outcomes results from 
institutional, regulatory, or other barriers.  In such cases, FDA has a unique role to play in 
closing this gap because it alone has access to all of the confidential business information 
provided by medical product developers who seek approval to market their products.  In 
addition, FDA regulates drug labels that convey to doctors how to use drugs in a manner known 
to be safe and effective.  
  In the next section of this paper, we provide background information on the uses and 
risks associated with warfarin dosing. We then describe the methods and assumptions we use to 
estimate the benefits associated with integrating genetic testing with warfarin therapy. In the 
following section we present our results, as well as the results of our uncertainty and sensitivity 




Warfarin has a problematic safety profile in part because it has a narrow therapeutic 
range and in part because patients vary greatly in the dose needed for adequate anticoagulation. 
The consequences of under-dosing and over-dosing are severe:  including elevated risk of death 
                                            
8 If the VKORC1 genotype is as widespread as the CYP2C9*2 and CPY2C9*3 polymorphisms and as useful as a 
guide to dosing, the benefits of integrating genetic typing with warfarin dosing could be twice as high as we have 
estimated here, Although we are not yet able to estimate the additional health benefits and cost savings from 
VKORC genotyping, the correlation between this genetic locus and warfarin metabolism strongly implies that the 
ranges of health benefits and cost savings shown in tables 2 and 3 likely understate the full gains from integrating 
genetic testing with warfarin therapy.   
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from stroke from under-dosing, and bleeding from over-dosing. The highest risk is the first 30 to 
60 days after beginning warfarin therapy. 
  Individual characteristics and behavior, such as sex and diet, account for the variation in 
appropriate warfarin dose across individuals. In addition, roughly one-third of the population 
carries one or both of the CYP2C9*2 and CPY2C9*3 polymorphisms that are associated with 
slower metabolization of warfarin, which in turn increases the likelihood of over-anticoagulation 
and the associated risk of serious bleeding.
9 Identifying persons with these genetic variants could 
allow physicians to prescribe more appropriate initial dosing of warfarin. Personalized dosing 
would reduce the number of serious adverse events and the associated costs of those adverse 
events to the health care system. 
We estimate the public health benefits and savings in health care costs that could accrue 
from more accurate, genotype-driven dosing decisions at the initiation of warfarin therapy. We 
take current medical outcomes and health care costs for those taking warfarin as the baseline, and 
then calculate the changes that would occur if the entire population of warfarin users underwent 
genetic testing. 
 
3. Assumptions and Methods 
 
To estimate the annual savings of health care costs attainable when genetic testing guides 
warfarin dosing, we employ estimates of the following variables: 
 
•  the number of people who start taking warfarin each year,  
•  the prevalence of variant genotypes among patients prescribed warfarin,  
•  the reduction in bleeding events from  more accurate dosing, 
•  the cost of bleeding events avoided,  
•  the reduction in strokes from more accurate dosing,  
•  the cost of strokes avoided, and  
•  the accuracy and cost of genetic testing.   
 
                                            
9 Mitchell K. Higashi et al., “Association Between CYP2C9 Genetic Variants and Anticoagulation-Related 
Outcomes During Warfarin Therapy.” JAMA 2002; 287: 1690-1698.  
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  All of these elements involve some uncertainty, which we build into our calculations 
through simulations and sensitivity analysis.  
 
4. Number and Prevalence of Varient Genotypes Among People Who Start Taking 
Warfarin Each Year 
 
  We estimate that roughly 2 million persons start taking warfarin in the United States 
annually.
 10 With more accurate dosing, that number could change but we do not build such a 
response into the model. We assume that genetic testing will identify a genotype for 95 percent 
of these 2 million, and fail to identify the genotype of 5 percent.
11 We further assume that one-
third of those whose genotype is identified are of variant genotypes.
12 Figure 1 illustrates the 












                                            
10 Data from IMS Health™, IMS National Sales Perspective™, 2005, extracted September 2005, shows that, in 
2005, in 2005, 7 to 10 million patient years of warfarin therapy were sold. This overstates the number of patients 
starting therapy each year, as many patients use warfarin for periods longer than a year. If the average patient uses 
warfarin 3 years, roughly 2 million individuals start warfarin therapy annually. 
11 Higashi et al. identified genotypes for 190 of 200 patients (95 percent). 
12 Thirty-eight percent of those genotyped in the Higashi et al. study were of warfarin sensitive genotypes. Other 
studies show the prevalence of Warfarin sensitive genotypes to be closer to 30 percent. We use 33 percent here as a 
middle estimate of prevalence. 
13 Higashi et al., tables 2 and 3. The labels on the figure (*1/*1, *1/*2, *2/*2, and so on) identify the non-variant (or 
“wild type”) and variant alleles of the enzyme CYP2C9.  
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Figure 1. Genotype Prevalence and Mean Daily Maintenance Dosing for Warfarin 
 
Circle area indicates relative population size. 
6 
*1/*1 
  Genotype Prevalence and Mean Daily Maintenance Dosing for Warfarin 
*1/*2  5 
 
  We base our estimate of the health gains from more accurate warfarin dosing on the 
recent paper by Higashi et al., which found that the mean maintenance dose for the variant 
population was much lower than the mean maintenance dose for the non-variant or “wild” 
14  
population. The study found 16 of the 58 variant carriers had serious or life-threatening bleeding 
events after initiation of warfarin therapy, as opposed to 16 of 127 in the non-variant population. 
If the numbers from their study are approximately representative of the entire population, then 
about 27.6 percent of the variant population taking warfarin experience adverse bleeding events, 
whereas 12.6 percent of the non-variant population experience such events. We use these results 
                                            










Non-Variant  Variant Genotypes 
Genotype 
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to generate a preliminary estimate of the potential reduction in the rate of serious and life-
threatening bleeding events.  
Lower initial dosing could reduce the rate of serious and life-threatening bleeding events 
in the variant population. Because we do not have data on the reduction in bleeding events 
among the variant population, we assume that accurate dosing would reduce the rate of adverse 
bleeding events in the variant population to the lower rate of the non-variant population. Under 
this assumption, more accurate warfarin dosing would reduce the incidence of serious bleeding 
in the variant population taking warfarin by approximately 15 percent (27.6 percent - 12.6 
percent).
15  
Testing has the potential to reduce not only the incidence of serious bleeding in warfarin 
therapy, but also the health care costs associated with serious bleeding, According to Ansell et 
al., most investigators categorize serious bleeding as bleeding associated with a defined drop in 
hemoglobin level, leading to transfusion of some number of units of blood or to hospitalization.
16 
The most common serious bleeding associated with warfarin use is gastrointestinal bleeding, 
followed by intracranial bleeding. You et al, estimates the average direct medical cost of 
gastrointestinal hemorrhage (with and without complication and co-morbidity) at $11,635 in 
2001.




5. Reduction in Strokes and Costs Saved from More Accurate Dosing 
 
  Correctly identifying non-variant individuals could also improve anticoagulation in the 
non-variant population if physicians, wary of bleeding risk, now under-dose or under-prescribe 
warfarin therapy. According to the Agency for Healthcare Research and Quality’s Healthcare 
Utilization and Cost Project, strokes account for over 400,000 annual hospital discharges. We 
assume that 10 percent of those strokes are preventable. Because we do not know the efficacy of 
more accurate warfarin dosing, we assume that 50 percent will be prevented by more accurate 
dosing. The actual efficacy may be lower or higher. We estimate the average stroke resulted in 
                                            
15 Higashi et al.  
16 Jack Ansell et al., “Managing Oral Anticoagulant Therapy,” Chest 2001; 119:22S-38S. 
17 Joyce H .S. You et al., “The Potential Clinical and Economic Outcomes of Pharmacogenetics-Oriented 
Management of Warfarin Therapy – A Decision Analysis.” Thromb Haemost. 2004; 92:590-597.  
18 Bureau of Labor Statistics, Consumer Price Index for Medical Care, 2002-2006. 
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$24,601 in hospitalization costs in 2002, 
19 and that hospitalization costs account for 70 percent 
of the first year direct costs of a stroke.
20  Adjusting these estimates for inflation, we calculate 
direct first year costs of about $39,500 per stroke.
 21 If these outcomes and costs could be 
reduced by genetic testing for CYP2C9 phenotypes, the cost savings and health gains would be 
large. Because we do not have any data to estimate the number of strokes avoided, we assume 
that better dosing through genetic testing would cut the number of preventable stroke in half.
22 
We use simulations to show the effect of different assumptions on the reduction in preventable 
strokes when genetic testing helps determine initial warfarin doses.  
 
6. Accuracy and Cost of Genetic Testing 
 
  The net benefits from more accurate dosing rely on the ability of the test to distinguish 
patients with variant genotypes from patients with non-variant genotypes, as well as the cost of 
the test.
23 Incorrectly identifying a variant carrier as a non-variant carrier could increase the risk 
of overdosing and bleeding, especially if genetic testing leads physicians to increase the initial 
warfarin dosing of non-carriers. Incorrectly identifying non-variant individuals as variants could 
similarly cause the non-variant population to be under-dosed, at least initially. Figure 2 








                                            
19 Weighted national estimates from HCUP Nationwide Inpatient Sample (NIS), 2002, Agency for Healthcare 
Research and Quality (AHRQ), based on data collected by individual States and provided to AHRQ by the States. 
20 Thomas N. Taylor et al., “Lifetime Cost of Stroke in the United States.” Stroke, 1996; 27: 1459-1466.  
21 Bureau of Labor Statistics, Consumer Price Index for Medical Care, 2002-2006. 
22 A recent review and meta-analysis suggests that this assumption understates the reduction in preventable strokes. 
See Matthew W. Reynolds et al, “Warfarin Anticoagulation and Outcomes in Patients with Atrial Fibrillation.” 
Chest 2004; 126: 1938-1945. 
23 Joyce H. S. You et al., “The Potential Clinical and Economic Outcomes of Pharmacogenetics-Oriented 
Management of Warfarin Therapy – A Decision Analysis.” Thromb Haemost. 2004; 92:590-597.  
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Figure 2. Testing Accuracy and Consequences 
 
•  True Positive 
o  Warfarin Sensitive 
Individual Correctly 
Identified 
o  Lower Initial Warfarin 
Dosing – Fewer Bleeding 
Events  
 
•  False Negative 
o  Sensitive Individual Falsely 
Identified as Non-Sensitive 
o  Higher Initial Warfarin 
Dosing Increases Risk of 
Bleeding Events  
•  False Positive 
o  Individual Incorrectly 
Identified as Sensitive 
o  Initial Warfarin Dose Too 
Low – Increased Stroke 
Risk 
•  True Negative 
o  Individual Correctly 
Identified as Non-Sensitive 
o  Higher Initial Warfarin 
Dosing Decreases Risk of 
Stroke 
 
We do not have data on the sensitivity and specificity of the genetic tests for these variant 
polymorphisms. For our baseline estimates of the effects of genetic testing, we assume that the 
rate of false positives and false negative is the same as the rate of inclusive tests. By one 
estimate, 5 percent of genetic tests for variant polymorphisms are inconclusive.
24 Allowing for 













                                            
24 Higashi et al. were unable to genetically type 10 of 200 blood samples. 
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Figure 3. Risk Profile for Warfarin Therapy Based on Genetic Testing 
 
 
correctly identifies 95 percent of variant population as variant and correctly identifies 95 percent 
of the non-variant population as non-variant. We also show the results for different sensitivities 
and specificities of the tests compared with the base case of 95 percent for both sensitivity and 
specificity. Figure 3 shows the health outcomes with and without genetic testing under these 
assumptions about the accuracy of the tests. 
The cost of genetic testing includes the cost of the test itself and the costs of drawing 
blood samples, making samples available for testing, and reporting results. Genelex, a private 
company offering direct to consumer genetic testing, charges approximately $250 for a single 
genetic test for CYP2C9 genotyping, although prices would be lower for a larger volume of tests. 
Genelex has done approximately 1,200 individual tests since 2000, implying that, if genetic 
testing were to be widely adopted, companies could charge less for testing, as the costs of testing 
equipment could be spread across more tests.  
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A new genetic test based on nanotechnology is also being developed. The test attaches 
gold nano-particles to genetic probes that are designed to bind to genetic variations in DNA. The 
nano-particles identify genetic variations by changing colors. This test has the potential to 
substantially reduce the cost of genetic testing for warfarin sensitive genotypes.
25
 We assume that the labor involved in drawing blood and related activities, such as record 
keeping, will be up to 3 hours. At a full compensation of about $33 per hour (for hospital 
workers)
26, the additional costs are about $100.   
 
Results 
  We estimate the health effects and the net change in health care costs associated with 
generic testing for warfarin dosing.
 27  We estimate the number of bleeding events avoided as the 
number of bleeding events prevented in persons with variant genotypes correctly identified (true 
positive tests) minus the number of bleeding events caused in persons with variant genotypes 
incorrectly identified as non-variant (false negative tests). Under the assumptions we have 
described, genetic testing would reduce serious bleeding events among the variant population in 
warfarin therapy by roughly 85,000 annually. If each event leads to health care costs of $13,500, 
genetic testing would reduce annual healthcare costs from bleeding events by about $1.15 
billion.  
We estimate the number of strokes avoided as the number of strokes avoided in non-
variants correctly identified (true negative tests) minus the number of stokes caused in patients 
with non-variant genotypes incorrectly identified as variants (false positive tests). The 
simulations also predict a reduction of about 17,000 strokes. If strokes, on average, lead to health 
                                            
25 Jon Van, “Small Innovation in Genetic Tests for Drugs.” Chicago Tribune, September 25, 2006. 
26 Bureau of Labor Statistics, Employer Costs for Employee Compensation: Health Care Employees in Hospitals, 
June 2006. 
27 For those patients with a genotype identified by the test, the following formulas give the possible test outcomes, 
where p is the frequency of variant genotypes, e is the probability of a false negative test for a variant genotype, and 
s is the probability of a false positive test for a variant genotype:  
1.  True negative, non-variant correctly identified: (1-p) x (1-e) 
2.  False positive, non-variant incorrectly identified: (1-p) x e 
3.  True positive, variant correctly identified: p x (1 – s) 
4.  False negative, variant incorrectly identified: p x s 
The health benefits are the strokes prevented among the true negative patients net of the additional strokes caused 
among the false positive patients, plus the bleeding events prevented among the true positive patients net of the 
bleeding events caused among the false negative patients.  
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care costs of $39,500, genetic testing would reduce healthcare cost by about $675 million per 
year.  
With full costs of genetic testing of about $350 per test, annual testing costs equal $700 
million (2 million tests x $350 per test). We estimate the net health care savings of integrating 
genetic testing into warfarin therapy to be about $1.1 billion ($1.15 billion in reduced bleeding 
costs + $675 million in reduced stoke costs - $700 million testing costs). From the standpoint of 
an individual patient or payer for that patient, the use of genetic tests reduced expected health 
care by about $900, at a cost of about $350 for an expected net saving of $550. 
28  These direct 
monetary savings substantially understate full social benefits because they do not include the 
value of the health improvements among warfarin users. 
 
 
Uncertainty and Sensitivity Analysis 
Monte Carlo simulations show, that with plausible assumptions about the distributions of 
the key variables, the public health benefits and cost savings of integrating genetic testing with 
warfarin therapy remain substantial. We derive the distributions for the bleeding events 
prevented from the values in Higashi et al. For stroke prevention, we have less quantitative 
information, so we use a uniform distribution (zero to 100 percent effectiveness) to model the 
uncertainty.
29  
The simulation incorporates uncertainty by using the distributions for many base values 
shown in Table 1. The results, shown in Table 2, contrast the mean outcomes with the 5
th and 
95
th percentile outcomes of the simulation. As the table shows, the 90 percent confidence 
intervals are 26,000 to 150,000 for serious bleeding events prevented, 1,690 to 32,700 for strokes 
avoided, and $70 million to $2.2 billion for net healthcare cost savings.    
These estimated benefits are most sensitive to the reduction in the rate of bleeding 
following genotype-based dosing, the reduction in preventable strokes, and the accuracy of 
testing. To show this sensitivity, we estimated the benefits using selected values for these key 
variables. The results of these calculations are shown in Table 3. 
                                            
28 We calculate the expected  gross cost savings per warfarin patient as bleeding cost savings plus stroke cost 
savings divided by the number of patients, or ($1.15 billion + $675 million)  / 2 million patients.  
29 We generated the mean results and the percentile estimates with a Monte Carlo computer simulation using 
Palisade™ @Risk™, version 4.5.  
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We assume that the reduction in the rate of serious bleeding is the difference between the 
rate in the variant and non-variant populations. The assumption that better dosing would reduce 
serious bleeding rates in the variant population to the same rate as that of the non-variant 
population has no basis in the evidence but is plausible. The reduction in the bleeding rate, 
however, could be less than or possibly even greater than the difference between the bleeding 
rates of the two populations in the Higashi et al. study. The estimates of the health gains are 
therefore too high if the reduction is less than the difference in bleeding rates, and too low if the 
reduction is greater than the difference. To show this sensitivity, we estimate benefits using the 
5
th percentile estimate of the difference in bleeding rates between variant and non-variant 
populations (5 percent) and the 95
th percentile difference (26 percent).  
The number of preventable strokes avoided is highly uncertain. We know that more 
aggressive warfarin dosing for the non-variant patient population will reduce strokes, but the 
percentage reduction could lie anywhere between zero and 100 percent. For the basic calculation, 
we chose the midpoint of 50 percent. In the simulations we use a uniform distribution running 
from zero to 100 percent. For the sensitivity analysis, we show the effects of a 5 percent and a 95 
percent reduction in preventable strokes.  
The accuracy of the genetic tests matters. The lower the rates of false positive and false 
negative tests, the greater will be the effectiveness of dosing based on those tests. For the basic 
calculations, we assume that 95 percent of tests identify the genotype as variant or non-variant. 
We further assume that 95 percent of the tests that identify patient genotypes as variant are 
correct and 95 percent of the tests that identify patient genotypes as non-variant are correct. We 
run sensitivity tests using 70 percent and 99 percent as alternative rates of sensitivity and 
specificity.  
We also include the sensitivity of the results to the costs of testing. We show the results 
for testing costs of $200 ($100 test plus $100 collection costs) and $500 ($400 test plus $100 
collection costs). Clearly, the lower the cost of testing, the higher are net healthcare savings. A 
low test cost reflects possible declines in the cost of the test as the amount of testing increases; a 
high test estimate reflect possible increases in costs that might occur if several tests are necessary 
to identify sub-variant genotypes.  
Table 3 shows the results of several of the sensitivity tests. As we expected, the results 
are highly sensitive to the effectiveness of warfarin dosing and the accuracy of the test. The cost 
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savings run from under $100 million per year to more than $2 billion, depending on the 
specification. Unless we assume low effectiveness for genotype-drive warfarin dosing, high rates 
of false positive and false negative tests, or extraordinarily high testing costs, the estimated 
healthcare savings remain positive.   
 
Conclusion 
  Rapid progress toward personalized medicine may require trials appropriate to 
justify changes to FDA-approved drug labels.  This analysis of warfarin illustrates that both 
public health improvements and significant reductions in health care spending may result from 
adoption of genetic information in clinical decisions about drug therapy. To generate estimates of 
health improvements and savings, we take current medical outcomes and health care costs for 
those taking warfarin, and then calculate the changes that would occur if the entire population of 
warfarin users underwent genetic testing that would be used to adjust initial doses of warfarin. In 
this case, the 85,000 serious bleeding events prevented and 17,000 strokes avoided come with a 
reduction in $1.1 billion in health care costs. The expected cost savings per patient exceed $500. 
Although these benefits estimates are quite uncertain, the existence of these benefits is much less 
so. Under many different plausible alternative assumptions, our analyses show that integrating 
genetic testing into warfarin therapy significantly improves health outcomes and reduces 
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Table 1. Values and Distributions Used to Estimate Health Benefits and Cost Savings 
 
  Mean or assumed value  Distribution 
Population of warfarin users   2 million per year  None. Benefits would 
change in direct proposition 
to the change in population. 
Probability of variant 
genotype 
33 percent  None. 
Frequency of test 
identifying a genotype 
Test identifies a genotype 
95 percent 
Beta (190,10) 
Accuracy of genotype 
testing 
Probability of false positive 
or false negative is 5 
percent; sensitivity and 
specificity are therefore 
both 95 percent 
Uniform (0, 10 percent)  for 
probabilities of false 
positive and false negative 
tests for variant genotypes 
Probability of bleeding 
event in variant population 
27.6 percent  Beta (16, 42) 
Probability of bleeding 
event in non-variant “wild” 
population 
12.6 percent  Beta (16, 111) 
Number of preventable 
strokes 
40,000 None. 
Reduction in preventable 
stokes following integration 
of genetic testing into 
warfarin therapy 
50 percent  Uniform (0,100 percent) 
Cost per severe bleeding 
event 
$13,500 None. 
Cost per stroke  $39,500  None.  
Test cost  $350. $250 for test plus 
$100 for costs of collecting 
and processing the sample 
Truncated normal: mean = 
$250, standard deviation = 
$50, minimum = $25, 
maximum = $475. Add 
$100 for costs of collecting 
and processing the sample. 
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Table 2. Health Benefits and Cost Savings 
(Dollar values are in millions per year) 
 
  Mean 5
th percentile  95th percentile 
Reduction in bleeding events   85,400  26,000  150,000 
Reduction in strokes  17,100  1,690  32,700 
Net healthcare cost savings  $1,130  $70  $2,240 
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Table 3. Selected Results of Sensitivity Analysis 
(Dollar values are in millions per year) 






Genetic testing reduces bleeding 
by 5 percent 
28,500 17,100  $347 
Genetic testing reduces bleeding 
by 26 percent 
148,200 17,100  $1,917 
Genetic testing reduces strokes 
by 5 percent 
85,400 1,710  $487 
Genetic testing reduces strokes 
by 95 percent 
85,400 32,490  $1,702 
Sensitivity and specificity of 
genetic test are both 70 percent 
38,000 7,600  $98 
Sensitivity and specificity of 
genetic test are both 99 percent 
93,000 18,600  $1,255 
Test cost is $100 plus $100 
collection costs 
85,400 17,100  $1,394 
Test cost is $400 plus $100 
collection costs 
85,400 17,100  $794 
    
 
   